Conduit Pharmaceuticals Long Term Debt

Conduit Pharmaceuticals (CDT) currently reports a long-term debt of $1.4B as of March 2026. That compares with $1.3B in the prior-year period — up 5.8% year over year. Use the charts on this page to explore Conduit Pharmaceuticals's long-term debt history and peer comparisons.

Conduit Pharmaceuticals's long-term debt increased from $1.3B to $1.4B — a 5.8% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Conduit Pharmaceuticals reported $1.4B in long-term debt as of March 2026. That compares with $1.3B in the prior-year period — up 5.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $1.4B, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Conduit Pharmaceuticals, and consider following CDT for alerts when major investors trade the stock.